SecurityGUAA / Guaranty Bancorp, Inc.
President & CEOTAYLOR PAUL W
Form 4 Count256
Form 8-K Count97
Form 10-Q Count19
Form 3 Count11

SEC Filings - 10K, 8K, Annual Reports

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Guaranty Bancorp, Inc.


DateFormTitle
2018-05-23 425 GUAA / Guaranty Bancorp, Inc. 425 (Prospectus)
2018-05-23 8-K GUAA / Guaranty Bancorp, Inc. 8-K (Current Report)
2018-05-23 425 GUAA / Guaranty Bancorp, Inc. 8-K (Prospectus)
2018-05-08 8-K GUAA / Guaranty Bancorp, Inc. 8-K (Current Report)
2018-05-01 10-Q GUAA / Guaranty Bancorp, Inc. 10-Q (Quarterly Report)
2018-04-18 8-K GUAA / Guaranty Bancorp, Inc. 8-K (Current Report)
2018-03-23 DEF 14A GUAA / Guaranty Bancorp, Inc. DEF 14A
2018-02-28 10-K GUAA / Guaranty Bancorp, Inc. 10-K (Annual Report)
2018-02-13 144 GUAA / Guaranty Bancorp, Inc. 144
2018-02-13 144 GUAA / Guaranty Bancorp, Inc. 144
2018-02-13 144 GUAA / Guaranty Bancorp, Inc. 144
2018-02-13 144 GUAA / Guaranty Bancorp, Inc. 144
2018-02-13 8-K GUAA / Guaranty Bancorp, Inc. 8-K (Current Report)
2018-01-30 8-K GUAA / Guaranty Bancorp, Inc. 8-K (Current Report)
2018-01-24 8-K GUAA / Guaranty Bancorp, Inc. 8-K (Current Report)
2018-01-16 8-K GUAA / Guaranty Bancorp, Inc. 8-K (Current Report)
2017-11-08 8-K GUAA / Guaranty Bancorp, Inc. 8-K (Current Report)
2017-11-07 8-K GUAA / Guaranty Bancorp, Inc. 8-K (Current Report)
2017-10-31 10-Q Guaranty Bancorp 10-Q (Quarterly Report)
2017-10-28 8-K Guaranty Bancorp 8-K (Current Report/Significant Event)
2017-10-18 8-K Guaranty Bancorp 8-K (Current Report/Significant Event)
2017-09-13 S-4/A Guaranty Bancorp S-4/A
2017-11-10 CORRESP GUAA / Guaranty Bancorp, Inc. ESP
2017-11-10 LETTER GUAA / Guaranty Bancorp, Inc. ER
2017-08-31 S-4 Guaranty Bancorp S-4
2017-08-09 8-K Guaranty Bancorp 8-K (Current Report/Significant Event)
2017-07-31 8-K Guaranty Bancorp 8-K (Current Report/Significant Event)
2017-07-28 10-Q Guaranty Bancorp 10-Q (Quarterly Report)
2017-08-18 144 Guaranty Bancorp 144
2017-08-18 144 Guaranty Bancorp 144
2017-08-18 144 Guaranty Bancorp 144
2017-08-18 144 Guaranty Bancorp 144
2017-07-19 8-K Guaranty Bancorp 8-K (Current Report/Significant Event)
2017-07-03 8-K Guaranty Bancorp 8-K (Current Report/Significant Event)
2017-05-09 8-K Guaranty Bancorp 8-K (Current Report/Significant Event)
2017-05-02 8-K Guaranty Bancorp 8-K (Current Report/Significant Event)
2017-04-28 10-Q Guaranty Bancorp 10-Q (Quarterly Report)
2017-04-19 8-K Guaranty Bancorp 8-K (Current Report/Significant Event)
2017-03-24 DEF 14A Guaranty Bancorp DEF 14A
2017-03-30 10-K Guaranty Bancorp 10-K (Annual Report)
2017-02-17 8-K Guaranty Bancorp 8-K (Current Report/Significant Event)
2017-02-08 8-K Guaranty Bancorp 8-K (Current Report/Significant Event)
2017-01-31 8-K Guaranty Bancorp 8-K (Current Report/Significant Event)
2017-01-25 8-K Guaranty Bancorp 8-K (Current Report/Significant Event)
2017-01-05 8-K Guaranty Bancorp 8-K (Current Report/Significant Event)
2016-12-16 424B3 Guaranty Bancorp 424B3 (Prospectus)
2017-04-06 LETTER Guaranty Bancorp ER
2017-04-06 CORRESP Guaranty Bancorp ESP
2016-12-07 S-3 Guaranty Bancorp S-3
2016-12-02 8-K Guaranty Bancorp 8-K (Current Report/Significant Event)

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

11h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...